Kenneth Frank

CIK 1587957 · SVP BioPharmaceutical Strategy · last filed 2014-10-08

Kenneth Frank is a SVP BioPharmaceutical Strategy who has filed 5 SEC Form 4 insider transactions across 1 company since 2013. The most recent filing, for PLL, was dated Oct 8, 2014.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

1

Total Filings

5

Lifetime Open-Market Net

$0

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
PALL CORP (PLL) Delisted	SVP BioPharmaceutical Strategy	8,896	$7.25	$64.5K	$0	5	2014-10-08

Recent Filings

5 filings

Form 4 transactions across all companies, newest first.

Filed	Symbol	Action	Net Shares	Net $	Link
2014-10-08	PALL CORP (PLL) Delisted	Mixed	+3,631	-$115.6K	EDGAR
2014-07-16	PALL CORP (PLL) Delisted	Mixed	+1,468	$120.7K	EDGAR
2013-12-13	PALL CORP (PLL) Delisted	Grant (A)	—	$0	EDGAR
2013-09-30	PALL CORP (PLL) Delisted	Mixed	+2,282	-$98.6K	EDGAR
2013-09-27	PALL CORP (PLL) Delisted	Mixed	+2,282	-$98.6K	EDGAR

Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.